Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | G6PD | P11413 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4062679 | 0.86 | LMNA (0.58) | LMNAALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL4853924 | 0.86 | HSD17B10 (0.60) | LMNAALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL8459523 | 0.86 | TSHR (0.60) | LMNAALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL6841859 | 0.86 | LMNA (0.52) | LMNAALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL6853371 | 0.80 | HSD17B10 (0.60) | LMNAALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL4976763 | 0.79 | LMNA (0.52) | LMNAALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL18617511 | 0.79 | LMNA (0.52) | LMNAALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL2421456 | 0.79 | CD44 (0.65) | LMNAALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL14049224 | 0.79 | LMNA (0.47) | LMNAALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL4544583 | 0.79 | CD44 (0.65) | LMNAALDH1A1GAAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020132603-A2 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-9334289-B2 | Cephem compound having catechol or pseudo-catechol structure | SHIONOGI & CO., LTD. (JP) | 2016-05-10 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20140088302-A1 | NOVEL CEPHEM COMPOUND HAVING CATECHOL OR PSEUDO-CATECHOL STRUCTURE | SHIONOGI & CO., LTD. (JP) | 2014-03-27 | — | — | US | disclosed |
| EP-2703406-A1 | NOVEL CEPHEM COMPOUND HAVING CATECHOL OR PSEUDO-CATECHOL STRUCTURE | Shionogi & Co., Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| EP-2409985-A2 | Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| EP-2314598-A1 | Inhibitors of Hepatitis C virus NS3 serine protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-27 | — | — | EP | disclosed |
| US-6759435-B1 | SUCH AS METHYL-(1-(2-(1-PHENYL-ETHYL)-PHENYL)-ETHYL)-AMINE; SEROTONIN REUPTAKE INHIBITORS | A.P. Group Inc. | 2004-07-06 | — | — | US | disclosed |
| WO-2000039088-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-07-06 | — | — | WO | disclosed |
| US-4596880-A | Pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 1986-06-24 | — | — | US | disclosed |
| US-4558129-A | Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade | SYNTEX (U.S.A.) INC. (US) | 1985-12-10 | — | — | US | disclosed |
| US-4499100-A | CARDIOUVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1985-02-12 | — | — | US | disclosed |
| US-4438275-A | 2,2-DIFLUORO-BENZODIOXOLES | BAYER AKTIENGESELLSCHAFT (DE) | 1984-03-20 | — | — | US | disclosed |
| US-4310540-A | PYRETHROID-LIKE COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1982-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088302-A1 | NOVEL CEPHEM COMPOUND HAVING CATECHOL OR PSEUDO-CATECHOL STRUCTURE | COMT, CMBL, CEP170 | LMNA 4194/4885ALDH1A1 908/4885GAA 92/4885 |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | LMNA 2931/4885ALDH1A1 1437/4885GAA 31/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | LMNA 3555/4885ALDH1A1 3320/4885GAA 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.